Praktische Konsequenzen der HOPE-Studie

Zusammenfassung

Die HOPE-Studie [15–18] wurde Anfang 2000 in mehreren Arbeiten publiziert. In dieser Übersicht sollen die praktischen Konsequenzen der HOPE-Studie in den Vordergrund gerückt werden. Dazu werden die Hypothesen der Studie, die wesentlichen methodischen Aspekte und die Hauptergebnisse zusammengefasst. Speziell wird wir auf die Bedeutung der Senkung des Blutdrucks und die neuen Daten bei Patienten mit Diabetes mellitus und mit Mikroalbuminurie eingegangen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

Literatur

  1. 1.
    Alderman MH, Madhavan S, Ooi WL, Cohen H, Sealey JE, Laragh JH (1991) Association of renin-sodium profile with the risk of myocardial infarction in patients with hypertension. N Engl J Med 324: 1098–1104PubMedCrossRefGoogle Scholar
  2. 2.
    Brunner HR, Laragh JH, Baer L (1972) Essential hypertension: renin and aldosterone, heart attack and stroke. N Engl J Med 286: 441–449PubMedCrossRefGoogle Scholar
  3. 3.
    Collins R, Peto R, MacMahon S et al. (1990) Blood pressure, stroke, and coronary heart disease. Part 2, short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 335: 827–839PubMedCrossRefGoogle Scholar
  4. 4.
    Garg R, Yusuf S (1995) Overview of randomized trials of ACE inhibitors on mortality and morbidity in patients with heart failure. JAMA 273: 1450–1456PubMedCrossRefGoogle Scholar
  5. 5.
    Guidelines Subcommittee (1999) 1999 World Health Organization–International Society of Hypertension Guidelines for the Management of Hypertension. J Hypertens 17: 151–183Google Scholar
  6. 6.
    Hansson L, Zancchetti A, Carruthers G, Dahlöf B, Elmfeld D, Julius S, Menard J, Rahn KH, Wedel H, Westerling S (1998) Effect of intensive blood pressure lowering and low-dose aspirin in patients with hypertension: principal results of the hypertension optimal treatment randomized trial. Lancet 351: 1755–1762PubMedCrossRefGoogle Scholar
  7. 7.
    Hilgers KF, Mann JFE (1996) Role of angiotensin II in glomerular injury: lessons from experimental and clinical studies. Kidney Blood Press Res 19: 254–262PubMedCrossRefGoogle Scholar
  8. 8.
    Linz W, Wiemer G, Gohlke P, Unger Th, Schölkens BA (1995) Contribution of kinins to the cardiovascular actions of ACE inhibitors. Pharmacol Rev 47: 25–49PubMedGoogle Scholar
  9. 9.
    MacMahon S, Peto R, Cutler Jet al. (1990) Blood pressure, stroke, and coronary heart disease. Part 1, prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 335: 765–774PubMedCrossRefGoogle Scholar
  10. 10.
    Mann JFE (1996) ACE-inhibition in chronic renal failure: a step forward. Nephrol Dial Transplant 11: 932–933PubMedGoogle Scholar
  11. 11.
    Mann JFE, Gerstein HC, Pogue J, Bosch J, Yusuf S (2001) Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomised trial. Ann Intern Med 134: 629–636PubMedGoogle Scholar
  12. 12.
    MRC Working Party (1992) Medical research council trial of treatment of hypertension in older adults: principal results. B M J 304: 405–412CrossRefGoogle Scholar
  13. 13.
    Ruggenenti P, Perna P, Gherardi G, Gaspari F, Benini F, Remuzzi G (1998) Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Lancet 352: 1252–1256PubMedCrossRefGoogle Scholar
  14. 14.
    Staessen JA, Gasowski J, Wang JG et al. (2000) Risks of untreated and treated isolated systolic hypertension in the elderly: meta-analysis of outcome trials. Lancet 355: 865–872PubMedCrossRefGoogle Scholar
  15. 15.
    The HOPE investigators (1996) The HOPE study: the design of a large, simple randomized trial of an ACE inhibitor (ramipril) and vitamin E in patients at high risk of cardiovascular events. Can J Cardiol 12: 127–137Google Scholar
  16. 16.
    The HOPE investigators (2000) Effects of an ACE inhibitor, ramipril, on cardiovascular events in high risk patients. N Engl J Med 342: 145–153CrossRefGoogle Scholar
  17. 17.
    The HOPE investigators (2000) Vitamin E supplementation and cardiovascular events in high risk patients. N Engl J Med 342: 154–160Google Scholar
  18. 18.
    The HOPE investigators (2000) Effects of ramipril on cardiovascular and microvascular o4tcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet 355: 253–259CrossRefGoogle Scholar
  19. 19.
    Wolf G (1999) Angiotensin II: a pivotal factor in the progression of renal disease. Nephrol Dial Transplant 14: s42 - s44CrossRefGoogle Scholar

Copyright information

© Steinkopff Verlag Darmstadt 2001

Authors and Affiliations

  • J. Mann
    • 1
  1. 1.Krankenhaus SchwabingLudwig-Maximilians-UniversitätMünchenDeutschland

Personalised recommendations